Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Allarity Therapeutics, Inc. (Nasdaq: ALLR), an emerging growth company, filed this Current Report on Form 8-K on March 25, 2022. The filing addresses a material accounting error requiring the restatement of previously issued financial statements for the quarters ended June 30, 2021, and September 30, 2021.
Key Financial Metrics and Material Changes
The filing does not provide updated revenue, profit, cash flow, or liquidity metrics. Instead, it details specific adjustments to prior period financial statements due to an accounting error regarding the valuation of derivative liabilities (TO3 Warrants).
- Accounting Error: Miscalculation of the fair value of 121,162,817 investor warrants issued in June 2021, allocation of offering costs, and reclassification of exercised warrants.
- Valuation Adjustment: Management corrected the valuation method to use probability-weighted Black-Scholes models. The probability-weighted value of TO3 Warrants was determined to be $2,000 (in thousands) as of June 24, 2021, and $2,100 (in thousands) as of June 30, 2021.
- Financial Impact: Warrants exercised on September 13, 2021, were re-valued at $206 (in thousands), resulting in finance costs of $393 (in thousands) allocated to the Consolidated Statement of Operations and Comprehensive Loss.
- Restatement Scope: The Company will restate the unaudited balance sheets as of June 30, 2021, and September 30, 2021, and the statements of operations for the three and six months ended June 30, 2021, and the three and nine months ended September 30, 2021.
Guidance, Risks, and Internal Controls
The filing identifies an additional material weakness in the Company's internal control over financial reporting for the periods ended June 30, 2021, and September 30, 2021. Management plans to devote significant resources to remediation, including enhanced access to accounting literature and increased communication with third-party professionals regarding complex accounting standards. The Chief Financial Officer has discussed these matters with the Company's auditors, Marcum LLP.
Investor Verification Checklist
- Verify the timing and content of the upcoming restated financial statements for the periods ended June 30, 2021, and September 30, 2021.
- Confirm the impact of the $393,000 finance cost adjustment on the Company's historical net loss and earnings per share.
- Monitor the Company's progress in remediating the identified material weakness in internal controls over financial reporting.
- Review the specific methodology used for the probability-weighted valuation of the TO3 Warrants in future filings.